title: [Thrombotic complications following the treatment of multiple myeloma with new agents].
abstract: Patients with multiple myeloma (MM) are at an increased risk of venous and arterial thrombosis. The risk factors and pathomechanisms for thrombotic complications in multiple myeloma patients can be divided into the disease-related and treatment-specific risk factors. With the introduction of novel therapies, including talidomide, lenalidomide and bortezomib, the outcomes of the patients with newly diagnosed or previously treated multiple myeloma have improved, however the treatment affected the prothrombotic and anticoagulant processes. The risk of venous thromboembolism (VTE) in patients receiving immunomodulatory agent-based regimens (thalidomide or lenalidomide), especially when used in combination with high-dose deamethasone- and/or anthracycline-based chemiotherapy is high. The proposed mechanisms for prothrombotic state include changes in von Willebrand factor, factor VIII, thrombomodulin, PAR-1 and COX-2 epression, and some abnormalities in transcription factors and genetic risk factors. Moreover, dysregulation of anticoagulation and impairment of fibrinolysis may also contribute to hypercoagulability state. The incidence of VTE in bortezomib-containing regimens is very low. It may be due to inhibitory effect of bortezomib on platelet aggregation and NF-kappa/beta. This article presents the latest outlook upon the pathogenesis of thrombotic complications in multiple myeloma patients undergoing the therapy with new agents.
authors.affiliation: Katedra i Klinika Hematologii i Chorób Rozrostowych Układu Krwiotwórczego, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu. joanna.rupa@best.net.pl
authors.forename: Joanna
authors.initials: J
authors.lastname: Rupa-Matysek
authors.forename: Lida
authors.initials: L
authors.lastname: Gil
authors.forename: Mieczysław
authors.initials: M
authors.lastname: Komarnicki
mesh_terms: D018943:Anthracyclines / Q000008:administration & dosage; D000925:Anticoagulants / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D004359:Drug Therapy, Combination / Q000009:adverse effects; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects*; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D013927:Thrombosis / Q000139:chemically induced* / Q000188:drug therapy
chemical_list: D018943:Anthracyclines; D000925:Anticoagulants; D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide